A C21 steroid hormone synthesized from Pregnenolone via cholesterol side-chain cleavage. Produced primarily by the corpus luteum during the luteal phase (days 14-28 of the menstrual cycle) and by the placenta during Pregnancy. Acts as a master immune modulator, driving Th2 polarization and establishing anti-inflammatory, pro-tolerance states essential for reproductive success and cyclical immune flexibility in women.
Think of progesterone as the diplomatic ambassador in the body's immune parliament. During the first half of the month (follicular phase), the parliament is hawkish β Th1 generals dominate, ready for combat against intruders. But after ovulation, progesterone arrives like a skilled negotiator who gradually shifts the entire chamber toward peaceful coexistence. She doesn't silence the generals completely, but she amplifies the voices of the Th2 peacekeepers who prefer to send antibodies rather than foot soldiers. She also boosts the IL-10 secretaries who spread calming messages throughout the chamber. This diplomatic shift is essential if a fertilized egg arrives β the fetus carries foreign paternal DNA, and without progesterone's calming influence, the immune system would attack it as an invader. When menstruation approaches and progesterone suddenly withdraws (like the ambassador leaving), the hawks immediately regain control, creating the pro-inflammatory pre-menstrual state. In the brain, progesterone acts like a gentle sedative β she modulates GABA receptors, the brain's "off switches," which is why low progesterone leaves women feeling anxious, insomniac, and emotionally raw before their period.
Cholesterol β Pregnenolone (via CYP11A1 in mitochondria)
Pregnenolone β Progesterone (via 3Ξ²-HSD in corpus luteum, adrenals, placenta)
Progesterone binds to intracellular progesterone receptors (PR-A and PR-B), which are ligand-activated transcription factors. Upon binding:
- PR dimerization β translocation to nucleus
- Binds to progesterone response elements (PREs) on DNA
- Recruits co-activators (SRC family proteins)
- Alters transcription of hundreds of immune-related genes
graph TD
P[Progesterone] --> PR[PR-A/PR-B Receptors]
PR --> N[Nuclear Translocation]
N --> G1["β Th1 Cytokines"]
N --> G2["β Th2 Cytokines"]
N --> G3["β Regulatory Signals"]
G1 --> IFN["β IFN-Ξ³"]
G1 --> IL2["β IL-2"]
G1 --> IL12["β IL-12"]
G2 --> IL4["β IL-4"]
G2 --> IL10["β IL-10"]
G2 --> IL13["β IL-13"]
G3 --> TREG["β Treg Cell Differentiation"]
G3 --> TGF["β TGF-Ξ² Expression"]
IFN --> CMI["β Cell-Mediated Immunity"]
IL4 --> HUM["β Humoral Immunity"]
IL10 --> TOL["β Immune Tolerance"]
Th1 Suppression:
- Inhibits IL-12 production from dendritic cells β blocks Th1 differentiation
- Downregulates IFN-Ξ³ and IL-2 production via NF-ΞΊB inhibition
- Reduces TNF-Ξ± synthesis by macrophages
Th2 Enhancement:
- Upregulates IL-4 and IL-13 β promotes B cell antibody production (IgG1, IgE)
- Increases IL-10 expression β anti-inflammatory macrophage phenotype
- Enhances GATA3 transcription factor β locks in Th2 commitment
Tolerance Mechanisms:
- Promotes Treg cells differentiation via TGF-beta upregulation
- Induces HLA-G expression at maternal-fetal interface (prevents NK cell activation)
- Increases Cortisol-binding globulin β enhances local cortisol availability
Progesterone is metabolized to Allopregnanolone (ALLO) by 5Ξ±-reductase and 3Ξ±-HSD:
Progesterone β 5Ξ±-DHP β Allopregnanolone
ALLO is a potent positive allosteric modulator of GABA-A receptors, increasing chloride influx β neuronal hyperpolarization β anxiolytic, sedative, anticonvulsant effects. This explains the calming effect of the luteal phase and the anxiety spike when progesterone crashes pre-menstrually.
- Increases basal body temperature (+0.3-0.5Β°C post-ovulation) via Hypothalamus thermoregulation
- Promotes mild Insulin resistance (preparing for potential pregnancy fuel demands)
- Stimulates respiratory drive (progesterone is a respiratory stimulant)
Menstrual Cycle Immune Tracking:
Progesterone creates a predictable monthly immune oscillation. Days 14-28 (luteal phase) are Th2-dominant: increased susceptibility to Allergy exacerbations, reduced autoimmune flares, enhanced wound healing. Days 1-13 (follicular phase, low progesterone) are Th1-dominant: better viral clearance, worsened autoimmune symptoms in conditions like rheumatoid arthritis and Multiple Sclerosis.
Fertility & Pregnancy:
Inadequate luteal-phase progesterone (<10 ng/mL at 7 days post-ovulation) signals corpus luteum dysfunction β recurrent miscarriage due to insufficient immune tolerance to the embryo. Progesterone supplementation (200-400 mg/day micronized vaginal or oral) is first-line for luteal phase defect and threatened early pregnancy loss.
PMS & PMDD:
The progesterone withdrawal (not low levels per se) 1-2 days before menstruation triggers the inflammatory shift plus loss of GABA modulation β anxiety, irritability, insomnia, mood lability. Women with PMDD show altered GABA-A receptor sensitivity to Allopregnanolone. Interventions: magnesium glycinate (400 mg/day), Vitamin B6 (50-100 mg/day as P5P), Agnus castus (20-40 mg/day standardized extract to increase progesterone synthesis).
Autoimmune Disease Patterns:
Evolutionary Context (Evolutionary mismatch):
Modern women experience 400+ ovulatory cycles vs. 50-100 in ancestral populations (due to late menarche, more pregnancies, extended lactation). This chronic progesterone cycling stress may contribute to hormone-sensitive cancers and inflammatory conditions. Clinical implication: consider cyclical anti-inflammatory support during luteal phase for women with chronic inflammatory states.
Biomarker Thresholds:
- Luteal phase serum progesterone: >10 ng/mL (>30 nmol/L) confirms ovulation
- Mid-luteal peak (day 21 of 28-day cycle): 10-25 ng/mL optimal
- Early pregnancy: doubles every 48h initially, reaches 10-30 ng/mL by week 6-8
- Progesterone/Oestradiol ratio: >300:1 (pg/mL units) suggests adequate luteal function
- Half-life: 5-7 minutes in circulation (rapidly metabolized by liver)
- Peak production: Corpus luteum secretes 25-50 mg/day during mid-luteal phase
- Pregnancy production: Placenta produces 250-350 mg/day by third trimester
- Basal body temperature rise: +0.3-0.5Β°C within 48h of ovulation due to progesterone's thermogenic effect on Hypothalamus
- Th1/Th2 shift timing: Begins 24-48h post-ovulation, peaks at day 21, collapses 24-48h pre-menstruation
- IFN-Ξ³ suppression: 40-60% reduction in Th1 cytokine production during peak luteal phase
- IL-10 elevation: 2-3 fold increase during luteal phase vs. follicular phase
- GABA potentiation: Allopregnanolone is 10x more potent than benzodiazepines at GABA-A receptors
- Miscarriage risk: Luteal progesterone <10 ng/mL associated with 35% miscarriage rate vs. 10% at >15 ng/mL
- Dosing for luteal support: 200-400 mg/day micronized progesterone (oral or vaginal) in assisted reproduction
- Non-genomic effects: Rapid membrane effects via mPRΞ± receptors (independent of nuclear PR) modulate calcium flux and neurotransmitter release
- Oestradiol β synergizes with progesterone to establish Th2 dominance; estradiol primes PR expression in target tissues
- Th2 β progesterone is the master driver of Th2 polarization during luteal phase and pregnancy
- Th1 β suppressed by progesterone via IL-12 and IFN-Ξ³ downregulation
- luteal phase β phase of menstrual cycle defined by elevated progesterone production from corpus luteum
- menstrual cycle β progesterone creates the immune oscillation pattern; withdrawal triggers menstruation
- IL-4 β upregulated by progesterone to promote Th2 differentiation and antibody class switching
- IL-10 β anti-inflammatory cytokine enhanced 2-3 fold during progesterone peak
- IFN-Ξ³ β pro-inflammatory Th1 cytokine suppressed 40-60% by progesterone
- Pregnancy β progesterone is essential for maintaining immune tolerance to fetal allograft
- corpus luteum β primary source of progesterone in non-pregnant state; rescued by hCG if fertilization occurs
- GABA β progesterone metabolite allopregnanolone potently enhances GABA-A receptor chloride conductance
- Allopregnanolone β neurosteroid metabolite of progesterone; anxiolytic and sedative via GABA modulation
- Cortisol β progesterone increases cortisol-binding globulin, enhancing local cortisol availability and anti-inflammatory effects
- TGF-beta β upregulated by progesterone to promote Treg differentiation and immune tolerance
- Treg cells β expanded by progesterone signaling to maintain pregnancy tolerance
- immune tolerance β progesterone is primary mediator of maternal-fetal tolerance via HLA-G, IL-10, Treg expansion
- Anxiety β progesterone withdrawal pre-menstrually causes loss of GABA modulation β anxiety spike
- Insulin resistance β mild insulin resistance induced by progesterone during luteal phase as metabolic preparation for pregnancy
- Hypothalamus β progesterone acts on thermoregulatory centers to raise basal body temperature post-ovulation
- rheumatoid arthritis β typically improves during high-progesterone states (pregnancy) and flares with progesterone withdrawal
- Multiple Sclerosis β relapse rate dramatically reduced during high-progesterone pregnancy, rebounds postpartum
- B cells β progesterone enhances IL-4 and IL-13 signaling to promote antibody production
- NF-ΞΊB β progesterone inhibits NF-ΞΊB nuclear translocation, reducing pro-inflammatory gene transcription